AbbVie shares have risen over 53% in 2024 driven by strong sales of immunology drugs Skyrizi and Rinvoq, which are offsetting Humira's decline faster than expected. However, the company faces challenges with a negative shareholders’ equity of -$6.6 billion and high debt of $72.86 billion, raising concerns about leverage and future patent cliffs. Analysts are divided, with a consensus price target suggesting 13% upside, but some models indicate significant downside. Investors are advised to watch upcoming earnings and pipeline developments before making major moves, as the stock balances strong growth potential against financial risks.
AbbVie announced final Phase 3 results from the CLL14 trial showing that a fixed-duration venetoclax plus obinutuzumab treatment significantly improves progression-free survival (PFS) in previously untreated chronic lymphocytic leukemia (CLL) patient...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
Verizon, Chevron, and AbbVie have all raised their dividends in 2026, appealing to retirees and income-focused investors seeking reliable payouts amid market volatility. Verizon offers a high yield of around 6% with strong cash flow and recent growth...
AbbVie received a Complete Response Letter from the FDA regarding its application for TrenibotE, a fast-acting botulinum neurotoxin serotype E for treating moderate to severe glabellar lines. The FDA's concerns were limited to manufacturing process d...
AbbVie presented new clinical data at the European Hematology Association (EHA) 2026 Congress showcasing progress in treatments for various blood cancers, including multiple myeloma, follicular lymphoma, and leukemia. Key highlights include promising...
